Clinical trials: Advanced Malignant Solid Tumours
Advanced Malignant Solid Tumors
Study Evaluating Safety And Tolerability, Solid Tumor
This is an open-label, phase 1 study of ascending multiple oral doses of HKI-272 in combination with paclitaxel.
- Trial name
- NCT00768469
- Testing
- Neratinib, Paclitaxel
- Where
- 2 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Puma Biotechnology, Inc.
Neoplasms, Malignant
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors
Primary Objective: To determine the maximum tolerated dose based on the incidence of dose limiting toxicity and the maximum administered dose of ombrabulin in combination with docetaxel and cisplatin administered every 3 weeks in…
- Trial name
- NCT01095302
- Testing
- OMBRABULIN (AVE8062), cisplatin, docetaxel
- Where
- 3 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Sanofi
mCRPC (Metastatic Castration-resistant Prostate Cancer), Advanced Malignant Solid Tumor
A Study of MHB048C in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB048C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07192120
- Testing
- MHB048C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Malignancies, Solid Malignant Tumor
JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
This is a Phase I, multicenter, single-arm, open-label clinical study designed to evaluate the safety and tolerability of JL19001 Injection as monotherapy (Phase Ia) or in combination with standard therapy (Phase Ib) in patients…
- Conditions
- Malignancies, Solid Malignant Tumor, NHL (Non-Hodgkin Lymphoma), Solid Tumor Cancer
- Trial name
- NCT07603479
- Testing
- JL19001, subcutaneous injection, 1 μg/kg, JL19001, subcutaneous injection, 5 μg/kg, JL19001, subcutaneous injection,10 μg/kg
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Tumor, Solid, Cancer, Metastatic
Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
This phase I trial is designed to efficiently identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) for the combination therapy regimen of the IDO1 inhibitor SHR9146 when administered in combination with…
- Conditions
- Tumor, Solid, Cancer, Metastatic, Neoplasm Malignant
- Trial name
- NCT03491631
- Testing
- SHR9146+SHR-1210, SHR9146+SHR-1210+Apatinib
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Malignant Solid Tumors
A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor
This is an open-label, phase 1 study of a single cohort of neratinib (HKI-272) in combination with capecitabine.
- Trial name
- NCT01128842
- Testing
- Neratinib, Capecitabine
- Where
- 2 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Puma Biotechnology, Inc.
Malignant Neoplasm of Digestive System
A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors
This study is an open-label Phase 1, First in Human trial of DR30303, a recombinant humanized monoclonal antibody that targets Claudin18.2 (CLDN18.2).
- Trial name
- NCT05639153
- Testing
- DR30303
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Glioma, Other Solid Tumours
A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours
This is a phase 1/2A, open label, non-randomized study in patients with advanced solid tumours including malignant glioma
- Trial name
- NCT01792310
- Testing
- LAM561
- Where
- 5 sites in Spain, United Kingdom
- Volunteers
- 54 people
- Sponsor
- Laminar Pharmaceuticals
Advanced Malignant Solid Tumors
HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors
A Phase I Study of HEC-921 Injection as Monotherapy and in Combination with Other AntineoplasticTherapy in Patients with Advanced Malignant Solid Tumors
- Trial name
- NCT07824934
- Testing
- HEC-921, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Advanced Malignant Solid Tumor
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors
VG2062 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to…
- Trial name
- NCT07262164
- Testing
- Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Virogin Biotech Co., Ltd.
Advanced Malignant Solid Tumors, Metastatic Malignant Solid Tumors
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
The purpose of this trial is to study the antibody GEN1057 when used as a single agent for the treatment of certain types of cancer.
- Trial name
- NCT06573294
- Testing
- GEN1057, Premedication
- Where
- 5 sites in United States, Japan and 1 more
- Volunteers
- 23 people
- Sponsor
- Genmab
Advanced Malignant Solid Tumors
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors
This study aims to evaluate the safety and efficacy of RCZY690 therapy in participants with advanced malignant solid tumors. Participants will receive RCZY690 monotherapy until the end of the study.
- Trial name
- NCT07806175
- Testing
- RCZY690 Tablets, RCZY690 tables
- Where
- 8 sites in China
- Volunteers
- 486 people
- Sponsor
- Rongchang Pharmaceuticals Co., Ltd.
NSCLC Adenocarcinoma, Solid Tumor
Atamparib in Patients With Advanced Solid Tumors
This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients…
- Trial name
- PARP7 (NCT07374419)
- Testing
- atamparib escalation levels, atamparib RP2D
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Nerviano Medical Sciences (Shanghai) Ltd.
Relapsed Malignant Solid Neoplasm
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced malignancies will be done to assess AUR107 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
- Trial name
- NCT05865002
- Testing
- AUR107
- Where
- 37 sites in India
- Volunteers
- 50 people
- Sponsor
- Aurigene Discovery Technologies Limited
Advanced Solid Tumor, Advanced Breast Cancer
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in…
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
- Trial name
- NCT06120283
- Testing
- BGB-43395, Fulvestrant, Letrozole
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 433 people
- Sponsor
- BeOne Medicines
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
- Trial name
- EVEREST-2 (NCT06051695)
- Testing
- A2B694, A2B543, xT CDx with HLA-LOH Assay
- Where
- 12 sites in United States
- Volunteers
- 474 people
- Sponsor
- A2 Biotherapeutics Inc.
Advanced Solid Tumors, Malignant Neoplasm
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery.
- Trial name
- NCT06818643
- Testing
- MK-3120
- Where
- 49 sites in United States, Chile and 10 more
- Volunteers
- 270 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors, Head and Neck Cancer
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Phase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- FPA008-003 (NCT02526017)
- Testing
- Cabiralizumab, Nivolumab
- Where
- 39 sites in United States
- Volunteers
- 313 people
- Sponsor
- Five Prime Therapeutics, Inc.
Advanced Malignant Solid Tumors
Bioequivalency Study of CM082 Tablet in Healthy Volunteers
The main objective of this study is to evaluate the bioequivalency of two preparations of CM082 tablet in Chinese healthy volunteers.
- Trial name
- NCT04328506
- Testing
- CM082 tablet (test product), CM082 tablet (reference product)
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AnewPharma
Advanced Cancer
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
The purpose of this study is to determine safety and effectiveness of experimental medication BMS-986205 in combination with Nivolumab in patients with cancers that are advanced or have spread.
- Trial name
- NCT03792750
- Testing
- BMS-986205, Nivolumab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb